I MAB 주식 가격. IMAB - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
I MAB (IMAB) 시세

I MAB (IMAB)

1.04

-0.02

(-1.89%)

마감 12 12월 6:00AM

1.065

0.025

( 2.40% )

시간외 단일가: 10:16PM

개인 투자자를 위한 전문가급 도구.

가격

1.065

매수가

1.05

매도가

1.07

거래량

1,373

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

1.04

개장가

-

최근 거래 시간

마지막 거래 시간

22:25:40

재정 규모

-

VWAP

-

평균 볼륨(3m)

-

발행 주식

80,701,592

배당수익률

-

주가수익률

0.00

주당순이익(EPS)

-

매출

27.64M

순이익

-1.47B

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.i-mabbiopharma.com

본부

Grand Cayman, Cym

설립됨

-

I MAB is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker IMAB. The last closing price for I MAB was US$1.04. Over the last year, I MAB shares have traded in a share price range of US$ 0.00 to US$ 0.00.

I MAB currently has 80,701,592 shares in issue. The market capitalisation of I MAB is US$83.93 million.

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab to Participate at the Piper Sandler Healthcare Conference PR Newswire ROCKVILLE, Md., Nov. 21, 2024 The 36th Annual Healthcare Conference will be held in New York, December 3-5...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Reports Third Quarter 2024 Results

I-Mab Reports Third Quarter 2024 Results PR Newswire ROCKVILLE, Md., Nov. 14, 2024 Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer PR Newswire ROCKVILLE, Md., Nov. 6, 2024 ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

I-Mab to Release Q3 2024 Financial Results on November 14, 2024 PR Newswire ROCKVILLE, Md., Oct. 31, 2024 ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 PR Newswire ROCKVILLE, Md., Oct. 30, 2024 - Poster to be presented in a late-breaking abstract session at the...

I-Mab to Participate at the Truist Securities BioPharma Symposium

I-Mab to Participate at the Truist Securities BioPharma Symposium PR Newswire ROCKVILLE, Md., Oct. 28, 2024 ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

가장 활성
% 상승자
% 패자

기호	가격	볼륨
PALIPalisade Bio Inc	US$ 2.89 (106.43%)	25.81M
TRVITrevi Therapeutics Inc	US$ 4.615 (85.34%)	13.92M
LAESSEALSQ Corporation	US$ 1.62 (40.87%)	22.36M
SYTASiyata Mobile Inc	US$ 0.993 (32.75%)	19.39M
WHLRWheeler Real Estate Investment Trust Inc	US$ 5.69 (27.58%)	1.64M
KROSKeros Therapeutics Inc	US$ 18.3166 (-73.32%)	1.51M
SPGCSacks Parente Golf Inc	US$ 0.5501 (-60.71%)	366.87k
TFFPTFF Pharmaceuticals Inc	US$ 0.0874 (-46.28%)	897.82k
AVGRAvinger Inc	US$ 0.443 (-45.98%)	174.64k
HEPAHepion Pharmaceuticals Inc	US$ 0.36 (-38.46%)	19
CDTConduit Pharmaceuticals Inc	US$ 0.1085 (22.88%)	50.9M
PALIPalisade Bio Inc	US$ 2.88 (105.71%)	25.81M
LAESSEALSQ Corporation	US$ 1.58 (37.39%)	22.6M
SYTASiyata Mobile Inc	US$ 0.9995 (33.62%)	19.4M
AMPGAmplitech Group Inc	US$ 2.25 (16.58%)	15.9M

glenn1919

glenn1919 2 월 전

IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2 월 전

IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 3 월 전

Monksdream

Monksdream 5 월 전

Monksdream

Monksdream 5 월 전

stock1ace1

stock1ace1 7 월 전

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

Monksdream

Monksdream 8 월 전

IMAB 10Q due 4/3

Monksdream

Monksdream 9 월 전

Monksdream

Monksdream 9 월 전

Monksdream

Monksdream 10 월 전

AGORDON

AGORDON 10 월 전

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

AGORDON

AGORDON 12 월 전

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

AGORDON

AGORDON 12 월 전

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

AGORDON

AGORDON 12 월 전

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

AGORDON

AGORDON 1 년 전

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

AGORDON

AGORDON 1 년 전

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

AGORDON

AGORDON 1 년 전

The stock has bounced off $1.80 two times within a month.

AGORDON

AGORDON 1 년 전

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

Mt. Blanc

Mt. Blanc 1 년 전

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

Monksdream

Monksdream 1 년 전

Vontobel Financial Produ...

Banca Aletti and C

Integrated System Credit...

BNP PARIBAS ISSUANCE

Crism Therapeutics

BNP Paribas Issuance

Bnp Paribas Issuance

BNP Paribas Issuance

Galleon Quest SEA Coin

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관